Track the AKTIS ONCOLOGY, INC. share price and the full management transaction log of the company, a listed equity based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Market capitalisation: €1.4bn. The latest transaction was filed on 21 July 2026 (Levée d'options). Among the most active insiders: Herrmann Ken. Every trade is accessible without an account.
25
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€3m
9 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate AKTIS ONCOLOGY, INC. Strong Buy (bullish), based on 6 analysts. Average price target: US$34.38.
41Σ signal
Buys n/a€3m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AKTIS ONCOLOGY, INC. is a company focused on developing innovative cancer treatments. It specializes in targeted therapies to improve patient outcomes.